Regeneron announces encouraging topline phase 2 data of high-dose aflibercept in wet age-related macular degeneration

Tarrytown, n.y., aug. 24, 2021 /prnewswire/ -- phase 3 trials in wet amd and diabetic macular edema fully recruited, with results expected in the second half of 2022 regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that an ongoing phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of eylea® (aflibercept) injection in patients with wet age-related macular degeneration (wet amd).
REGN Ratings Summary
REGN Quant Ranking